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Recent human immunodeﬁciency virus type 1 (HIV-1) vaccination strategies aim at targeting a broad
range of cytotoxic T lymphocyte (CTL) epitopes from diﬀerent HIV-1 proteins by immunization with
multiple CTL epitopes simultaneously. However, this may establish an immune hierarchical response,
where the immune system responds to only a small number of the epitopes administered. To evaluate
the feasibility of such vaccine strategies, we used the human leukocyte antigen (HLA)-A*0201 trans-
genic (tg) HHD murine in vivo model and immunized with dendritic cells pulsed with seven HIV-
1-derived HLA-A*0201 binding CTL epitopes. The seven peptides were simultaneously presented on
the same dendritic cell (DC) or on separate DCs before immunization to one or diﬀerent lymphoid
compartments. Data from this study showed that the T-cell response, as measured by cytolytic activity
and c-interferon (IFN-c)-producing CD8
+ T cells, mainly focused on two of seven administered epi-
topes. The magnitude of individual T-cell responses induced by immunization with multiple peptides
correlated with their individual immunogenicity that depended on major histocompatibility class I
binding and was not inﬂuenced by mode of loading or mode of immunization. These ﬁndings may have
implications for the design of vaccines based on DCs when using multiple epitopes simultaneously.
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To meet the high diversity of human immunode-
ﬁciency virus type 1 (HIV-1) and to avoid viral
cytotoxic T lymphocyte (CTL) escape from the
immune system (1), it is desirable to target a
broad range of epitopes encoded by distinct pro-
teins in the HIV-1 genome, thereby increasing
the coverage of the vaccine. This principle may
involve polytope DNA constructs encoding
several CTL epitopes (2) or the use of multiple
peptides delivered by dendritic cells (DCs) (3–5)
and other adjuvants (6). CD8
+ T cell (CTL)
responses generated against antigens that carry
several potential CTL epitopes may focus on a
minority of epitopes selected by the immune Received 1 June 2009. Accepted 8 September 2009
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849response in vivo, a phenomenon known as
immunodominance (7). Immunodominance is
inﬂuenced by antigen processing (7, 8), aﬃnity
for the major histocompatibility class I (MHC-I)
molecule (9), and direct competition among
T cells of the same speciﬁcity (10) or diﬀerent
speciﬁcities (11).
In this study, we aimed to elucidate the
mutual competition among 7 HLA-A*0201
binding HIV-1-derived CTL epitopes (12).
These vaccine-relevant CTL epitopes were pre-
sented together with a CD4
+ T-helper peptide
either separately or simultaneously on bone
marrow-derived DCs and immunized in one or
two diﬀerent anatomic sites of HLA-A*0201
transgenic mice draining to the same or diﬀerent
lymph nodes. We found that the CTL responses
focused mainly on the two epitopes with the
highest binding aﬃnity to HLA-A*0201.
MATERIALS AND METHODS
HLA-A*0201 transgenic mice
The HHD transgenic mice kindly provided by
F.A. Lemonnier, Institut Pasteur, Paris, France,
express a transgenic monochain histocompatibility
class I molecule in which the C-terminus of the
human b2-microglobulin (b2m) is covalently linked to
the N-terminus of a chimeric heavy chain (HLA-A2.1
a1-a2, H-2D
b a3-transmembrane and intracytoplas-
mic domains). HHD mice are homozygous for the
transgene, H-2D
b) ⁄ ) and b2m
) ⁄) double knockout.
Peptides and HLA-A*0201-binding
Epitope peptides identiﬁed as relevant for HIV-1
vaccination (12, 13) were synthesized by Schafer-N,
Copenhagen, Denmark. Peptide-binding aﬃnities to
puriﬁed HLA-A*0201 molecules were measured using
an in vitro biochemical binding assay (14). Brieﬂy,
pre-oxidized MHC-I molecules when diluted into a
reaction buﬀer containing human b2m and the appro-
priate test peptide, fold rapidly and eﬃciently only in
the presence of the test peptide.
Generation of mature DCs from bone marrow cells and
peptide loading
Bone marrow cells from HHD transgenic mice were
kept overnight in culture medium [RPMI 1640 with
10% (v⁄v) FCS, 1% (v⁄v) penicillin, streptomycin,
1 & (v⁄v) 2-mercapta-ethanol] and the non-adhering
cells were cultured with GM-CSF, 10 ng⁄ml, and
IL-4, 20 ng⁄ml (PreproTech Inc., Rocky Hill, NJ,
USA). At day 3, fresh culture medium with GM-CSF
and IL-4 was supplied. At day 6, the cells were har-
vested and cultured overnight with GM-CSF, IL-4
and 1 lg⁄ml of LPS (Sigma, St. Louis, MO, USA).
At day 7, the mature DCs were harvested and used
for vaccination.
Mature DCs were either loaded with a single
peptide for individual peptide immunogenic ranking
or loaded with peptides in four diﬀerent combinations
at a concentration of 10 lg⁄ml⁄peptide (Fig. 1).
Vaccination protocols were performed as follows:
(i) all seven peptides were loaded onto the DCs
simultaneously, washed thoroughly, resuspended in
phosphate-buﬀered saline (PBS) and injected intracu-
taneously (i.c.) in one ﬂank of the mouse. (ii) The
same number of DCs was aliquoted in seven vials and
pulsed separately with one peptide for each vial, then
washed thoroughly and mixed in one syringe followed
by i.c. injection in one ﬂank of the mouse. (iii) Pep-
tides were loaded separately onto DCs as described in
group B, but just prior to injection, epitopes ranked
1–3 according to their individual immunogenicity
(Table 1) were pooled and administered in the left
ﬂank of the mouse and epitopes ranked 4–7 (Table 1)
were pooled and administered in the right ﬂank of the
mouse. (iv) Epitopes ranked 1–3 (Table 1) and 4–7
A
1-7
4-7 1-3
1
1
2
2
3
3
4567
4567
B
C
D
Fig. 1. Illustration of four diﬀerent modes of
dendritic cell (DC) loading and immunization. (A)
All seven peptides were loaded onto the DCs simulta-
neously and injected intracutaneously (i.c.) in one
ﬂank of the mouse. (B) The same number of DCs was
aliquoted in seven vials and pulsed separately with
one peptide for each vial and mixed in one syringe fol-
lowed by i.c. injection in one ﬂank of the mouse. (C)
Peptides were loaded separately onto DCs as
described in group B, but prior to injection, epitopes
ranked 1–3 (Table 1) were pooled and administered
in the left ﬂank of the mouse and epitopes ranked 4–7
(Table 1) were pooled and administered in the right
ﬂank of the mouse. (D) Epitopes ranked 1–3 and 4–7
(Table 1) were loaded onto DCs in two separate vials
followed by i.c. injection in the left and right ﬂanks of
the mouse, respectively.
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followed by i.c. injection in left and right ﬂank of the
mouse, respectively. A CD4
+ T helper peptide
PADRE (15) was included with each CTL epitope
peptide to provide necessary CD4 T-cell help. Each
mouse received 3 · 10
6 DCs for individual peptide
response or alternatively 1.3 · 10
6 pulsed DCs for
each peptide resulting in 9 · 10
6 DCs in total for
every mouse in the competition experiments.
HLA-A*0201 transgenic mice immunizations
HHD transgenic mice, 8–12 weeks old, were injected
i.c. in the ﬂank with matured DCs pulsed with the
relevant HLA-A*0201-binding HIV-1 CTL peptide
and a T-helper peptide PADRE as described above
(15). DCs were resuspended in 100 ll PBS for each
injection. At day 11 after vaccination, mice were
sacriﬁced and the splenocytes were recovered and
re-stimulated with the vaccination-peptide as
described previously (13). After 5 days, the CTLs
were used for ﬂow cytometric analysis or harvested
and depleted of NK and B cells using anti-CD49b
antibodies and anti-CD19 antibodies (Mylteneyi Bio-
tec, Gladbach, Germany), respectively. Cells were
depleted on a column, MACS LS, according to the
manufacturer’s protocol. The non-depleted cells were
then used directly for cytolytic
51Cr-release assays
and IFN-c ELISpot assays.
Flow cytometry
Splenocytes cultured for 5 days were stimulated for
2 h with 2 lg⁄ml peptide antigen and subsequently
incubated for 5 h with protein transport inhibitor
(BD GolgiStop; BD Pharmingen, San Diego, CA,
USA) at 37  C and 5% CO2. Thereafter, cells were
stored overnight in 4  C. Due to the low frequency of
CD8
+ T cells in this HHD
+ transgenic mouse model,
CD8
+ T cells were negatively isolated using a CD8a
+
T cell isolation kit (Miltenyi Biotec, Teterow,
Germany) according to the manufacturer’s protocol,
followed by surface staining using anti-CD3-PerCP
(BD Pharmingen) and anti-CD8-FITC (BD Pharmin-
gen). Cells were washed and subsequently ﬁxed and
permeabilized using the Fix and Perm kit (Caltag
Laboratories, Der Grub, Austria) and stained intra-
cellularly with anti-IFN-c-Allophycocyanin (APC)
(BD Pharmingen) and anti-tumor necrosis factor-a
(TNF-a)-Phycoerythrin (PE) (BD Pharmingen). Cells
were washed and resuspended in staining buﬀer prior
to immediate ﬂow analysis. Data were acquired on a
BD LSRII instrument using FACSdiva software (BD
Biosciences) and analyzed with FACSdiva or FlowJo
software (TreeStar, Ashland, OR, USA).
IFN-c enzyme-linked immunospot (ELIspot) assay
A standard IFN-c ELISpot assay was used as
described previously (13). Cells, with titration of cells
ranging from 300 000 to 18 750 each performed in
triplicate, were stimulated with 10 lg of antigen⁄ml
for 18 h of incubation at 37  C, 5% CO2. Spot-form-
ing units were quantiﬁed using an automatic system
ELR02 ELISPOT reader (Autoimmun Diagnostika
GmbH, Strassberg, Germany) and analyzed with
AiD3.1 S.R software.
Cytotoxic T lymphocyte chromium release assay
A standard cytotoxic
51Cr-release assay was used as
described previously (13). Brieﬂy, HHD-EL4S3
-Rob
target cells (16) were mixed with peptide loaded
splenocyte eﬀector cells at eﬀector:target cell ratios
(E:T) of 100:1, 50:1, 25:1 and 12.5:1 in either tripli-
cates or six replicates.
51Cr-release was measured
Table 1. Immunogenicity of seven HIV-1-derived HLA-A*0201-binding synthetic peptides
Epitope Sequence Rank
1 IC50 (nM) Speciﬁc
lysis (%)
2
SFU⁄mio
splenocytes
3
IFN-c
+TNF-a
+4
Gag150
mod RLLNAWVKV 1 26 66 ± 1.2 19657 ± 1774 16.6
Gag433 FLGKIWPS 2 3 49 ± 2.7 5714 ± 575 12.6
Vif23(9V) SLVKHHMYV 3 168 46 ± 3.6 4217 ± 146 5.0
Pol606
mod KLGKAGYVV 4 384 36 ± 3.7 4391 ± 370 3.2
Env67(2I) NIWATHACV 5 103 28 ± 0.8 3658 ± 223 3.6
Vif101(9L) GLADQLIHL 6 219 17 ± 0.9 nd 2.5
Vpu66
mod ALVEMGHHV 7 334 No lysis nd 2.2
Values represent data from groups of four mice with pooled splenocytes. HIV-1; human immunodeﬁciency virus
type 1; HLA, human leukocyte antigen; SFU, spot-forming unit; IFN-c, c-interferon; TNF-a, tumor necrosis
factor-a; nd, not determined.
1Epitopes are ranked according to decreasing immunogenicity.
2Mean values at eﬀector target ratio 50:1, ± indicate SD of triplicates.
3Mean values, ± indicate SD of triplicates.
4Values represent percentage double-positive IFN-c and TNF-a-producing CD3
+CD8
+ T cells from pooled
splenocytes (n = 4 mice) in order to obtain suﬃcient cell counts for optimal analysis.
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NXT; Packard, Boston, MA, USA). Spontaneous
and total
51Cr-release was measured by adding
culture medium or a detergent (Triton X-100) 2%
v⁄v, respectively. The percentage of speciﬁc lysis
was calculated as 100 · (experimental release ) spon-
taneous release)⁄(total release ) spontaneous
release). Spontaneous and total release was in the
range of 1200 and 9000 counts per minute, respec-
tively.
RESULTS
Immunogenicity of individual peptides
To evaluate the individual immunogenicity of
the minimal HIV-1-derived HLA-A*0201-bind-
ing CTL epitopes we immunized HLA-A*0201
tg mice with DCs pulsed with the individual
CTL epitope. We used a standard speciﬁc cell
killing assay (chromium release), conﬁrmed by
intracellular cytokine staining (ICS) and ELI-
Spot assays (Table 1). We found that each of
the seven CTL epitopes tested exhibited diﬀer-
ential immunogenicity in vivo, with the two Gag
epitopes Gag433 and Gag150
mod being the most
immunogenic CTL epitopes. The immunogenic-
ity was comparable with the HLA-A*0201 bind-
ing aﬃnity where the two Gag peptides bind
better than 100 nM and the remaining peptides
bind in the intermediate 100 nM < IC50 <
500 nM range (Table 1). For further in vivo
competition experiments when immunizing mul-
tiple CTL epitopes simultaneously we ranked
the seven CTL epitopes with respect to immuno-
genicity measured by functional lytic activity
(Table 1).
In vivo competition is not reduced by pulsing epitopes
separately on DCs
We examined whether immune competition
would occur and could be changed by present-
ing epitopes either separately or simultaneously
on bone marrow-derived DCs prior to immuni-
zation in HLA-A*0201 transgenic mice. This
was done by pulsing all seven peptides in one
vial vs pulsing all seven peptides in seven indi-
vidual vials of DCs as illustrated in Fig. 1A,B,
respectively. These experiments were repeated
three times. By simultaneous immunization,
a hierarchy was established where Gag150
mod
and Gag433 responses dominated (Fig. 2).
Irrespective of whether the epitopes were pulsed
separately before pooling, or pulsed together
onto DCs, the resulting in vivo hierarchy was
virtually unchanged as measured by cytolytic
and ELISPOT assays. One representative exper-
iment is shown in Fig. 2. These data were con-
ﬁrmed in another experiment using IFN-c,
TNF-a and IL-2 ICS (data not shown). In some
experiments with individual pulsing or grouping
according to the ranking shown in Table 1, up
to three additional epitopes showed a weak
response in some assays, as Vif23 in Fig. 2B.
However, these weaker responses were not con-
sistent.
In vivo competition is not reduced by separating
epitopes and immunizing diﬀerent lymphoid
compartments
We then hypothesized whether we could
overcome the immunodominance of Gag433,
Gag150
mod and Vif101, ranked 1–3 in Table 1, by
homing DCs loaded with more dominant CTL
epitopes and DCs loaded with less dominant
CTL epitopes, to the same or diﬀerent lymphoid
compartments, respectively. We immunized
dominant and less dominant CTL epitopes sep-
arately in the right and left ﬂank of the mouse,
respectively, as indicated in Fig. 1C,D. Admin-
istration of dominant and less dominant
peptides in diﬀerent lymphoid compartments
did not increase the breadth or the magnitude of
CTL responses in vivo (Fig. 2C,D). Again, the
epitopes Gag150
mod and Gag433 dominated the
responses in three individual experiments (Fig. 2).
DISCUSSION
Immunodominance in the context of CTL epi-
topes is inﬂuenced by a number of factors
including the T-cell precursor repertoire (10),
T-cell access to the antigen-bearing APC (10),
TCR aﬃnity for the antigen (17), antigen aﬃn-
ity for MHC-I and the processing of antigen (7).
In this study we evaluated whether multi-
epitope immunization would change the immu-
nogenicity of individual epitopes and whether
diﬀerent modes of DC immunization would
change or reduce any immunodominance and
thereby broaden the T-cell responses. We used
seven HIV-1-derived CTL epitopes each found
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Freund’s incomplete adjuvant (12) and by indi-
vidual peptide DC immunization (Table 1).
When peptides were delivered simultaneously
on the same DC, separate DCs and⁄or distrib-
uted to diﬀerent lymphoid compartments the
CTL response focused mainly on two epitopes,
Gag150
mod and Gag433. Interestingly the
Gag150mod
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Fig. 2. Two of seven epitopes dominate the T-cell responses. Chromium release cytotoxic T lymphocyte (CTL)
assay and IFN-c ELISpot assay were used to measure the breadth and magnitude of T-cell responses. (A) (B) (C)
and (D) are illustrated in Fig. 1A–D, respectively, and explained in the legend to Fig. 1. Groups of six mice were
used for immunization and pooled splenocytes were tested against all seven CTL epitopes and one irrelevant neg-
ative control peptide (mock). SFU, spot-forming unit. One representative experiment of three is shown.
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mod, Vpu66
mod,
Vif101 and Env67 showed weaker and inconsis-
tent responses compared to their immunogenic-
ity when delivered with DC alone. This
phenomenon was virtually unchanged using the
diﬀerent modes of immunization with seven epi-
topes.
The observed immunodominance for
Gag150
mod and Gag433 cannot be explained by
intracellular preference for antigen processing,
because all peptides were loaded onto mature
DCs in a pre-processed form. Instead, the diﬀer-
ent epitope HLA-A*0201-binding aﬃnities
(Table 1) may explain the immunodominance
pattern, where Gag150
mod and Gag433 had the
highest binding aﬃnities to HLA-A*0201
(IC50 < 100 nM). This is in line with previous
ﬁndings that also relate high MHC-I aﬃnity
and immunodominance (7, 18) where good
immunity is induced by peptide epitopes bind-
ing better than 100 nM, and no immunogenicity
by MHC-I processing either in the intermediate
range 100 < IC50 < 500 nM or in the no
MHC-I binding range IC50 > 500 nM (9, 12).
Peptide competition for the MHC-I molecule
may impact on the output response in vivo (18,
19). However, peptide competition for the APC
does not seem to obscure the dominance pattern
in our system, where approximately the same
CTL epitopes stimulate responses when anti-
gens are delivered on the same DC or on sepa-
rate DCs. These ﬁndings are in contrast to
previous reports, which suggest that T-cell com-
petition is decreased when antigen is presented
on diﬀerent APCs (11, 20). This may be due to
the relatively high numbers of DCs used for
immunization, where 1.3 · 10
6 pulsed DCs for
each peptide resulting in a total of 9 · 10
6
DCs are injected into each mouse. Instead, it
appears in our model that TCR aﬃnity for the
antigen largely impacts the immune hierarchy.
The very low number of naı¨ve CD8
+ T cells
speciﬁc for a given antigen in the very early
phase of a primary response makes competition
at this stage unlikely (21). However, as the pro-
liferation of these speciﬁc cells increases, compe-
tition for persistent TCR stimuli will be
established, especially among cells of the same
clone and avidity occupying the same niche in
the lymphoid compartment (22), possibly
explaining the cross-competition observed in
this study.
In a recent phase I trial of therapeutic immu-
nization using the same minimal CTL epitope
peptides and DC in 12 HLA-A0201
+ HIV-1
+
individuals, we used an immunization strategy
similar to D in Fig. 1. Although diﬀerent
immune reaction patterns were observed in indi-
vidual patients, all epitopes were immunogenic,
inducing new immunity in at least one patient as
measured by ICS and⁄or pentamer staining (5).
The most frequent targeted epitope was
Pol606
mod followed by Vif23, Gag433, Env67,
Gag150
mod, Vif101 and Vpu66
mod. The fact that
the immune hierarchy seen in HLA-A2tg mice
did not translate into humans may be due to
several reasons: the assays used for evaluation
were diﬀerent, in humans we used ICS and pent-
amer staining and in mice we used cytotoxic
51Cr-release and IFN-c ELISPOT. The HLA-
A2tg mice are homozygous for the HLA-
A*0201 transgene and H-2D
b)⁄) knockout,
whereas although all individuals in the human
study were HLA-A0201
+, epitope promiscuity
and aﬃnity to other HLA alleles likely inﬂuence
the immune hierarchy (23). Moreover, HIV-1
+
individuals have, before this therapeutic vacci-
nation, been exposed to these HIV-1-derived
epitopes.
Our results show that the two epitopes
Gag150
mod and Gag433 established themselves as
dominant in the context of the seven epitopes
tested, whereas the remaining ﬁve epitopes
established themselves as subdominant in the
multi-epitope context chosen. It appears that
binding aﬃnity to MHC-I is the determining
factor in the established hierarchy that could
not be avoided or changed by the diﬀerent
modes of immunizations used here. Although,
HLA-A0201
+ HIV-1-infected humans and
HLA-A*0201tg mice may react diﬀerently.
These ﬁndings may have implications for
DC-based vaccine strategies that intend to
optimize administration of multiple antigens
concurrently.
We gratefully acknowledge Dr. Philippa Matthews
for helpful discussions and reading of the manuscript.
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